Bionique Testing Laboratories, Inc., Lonza and bioMérieux SA are Dominating in the Global Mycoplasma Testing in Clinical Market in 2019

Global Mycoplasma Testing in Clinical Market is expected to grow with the CAGR of 7.0% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://databridgemarketresearch.com/reports/global-mycoplasma-testing-in-clinical-market

Global mycoplasma testing in clinical market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global mycoplasma testing in clinical market are introducing strong range of products along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the mycoplasma testing in clinical market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in November 2017, Bionique Testing Laboratories, Inc. had presented a presentation on the topic of Advance in Biotechnology & Microbiology. This presentation allowed the company to aware healthcare professionals and patients about the company’s wide product portfolio used for mycoplasma detection in clinical setting.

Bionique Testing Laboratories, Inc. is the dominating player in global mycoplasma testing in clinical market. The other key players existing in the mycoplasma testing in clinical market are AB ANALITICA s.r.l., bioMérieux SA, ELITechGroup, Liofilchem S.r.l., Agilent Technologies, Inc., PromoCell GmbH, F. Hoffmann-La Roche Ltd, OSANG Healthcare, Sacace Biotechnologies Srl, Lonza, Merck KGaA, Seegene Inc., Clongen Laboratories, LLC, Bio-Rad Laboratories, Inc., Charles River Laboratories, and ZEAKON Diagnostics among others.

MYCOPLASMA TESTING IN CLINICAL MARKETBionique Testing Laboratories, Inc.:

Bionique Testing Laboratories, Inc. is headquartered in New York, U.S. and was founded in 1990. The company is focused on evolving into a global leading provider of mycoplasma testing services for the life science industry. The company has wide range of product & service categories involving cell culture testing, lot release testing, raw materials testing, mycoplasma clean-up & elimination and other products & services.

For instance,

  • In July 2018, Bionique Testing Laboratories, Inc. expanded its leadership team with the addition of new commercial expertise. This initiative by the company allowed it to grow its business via strong manpower involving its business of mycoplasma detection kits among others.

The company has presence across North America.

Lonza:

Lonza is headquartered in Basel, Switzerland and was founded in 1897. The company focuses on providing treatments that prevents illness and supports healthier lifestyles by creating a healthy environment. The company operates its business through two business segments which are pharma biotech & nutrition and specialty ingredients in which pharma biotech & nutrition is the market focused segment. The company has various product categories which are pharma & biotech, capsules & health ingredients, microbial control solutions and specialty chemical services in which pharma & biotech is the market focused product category.

For instance,

  • In March 2019, Lonza expanded the mycoplasma detection product portfolio with the introduction of new luminometer, a product designed for simplify and accelerating the testing procedure. This initiative helped Lonza to strengthen its extensive mycoplasma detection portfolio with the addition of new products.

The company has presence across North America, Asia-Pacific, Europe, South America and Middle East & Africa. The company has various subsidiaries which are Lonza Netherlands B.V. (Netherlands), Lonza America, Inc. (America), Arch Quimica Argentina S.R.L. (Argentina), Lonza Guangzhou Ltd (China), Cambrex France SARL (France) among others.

bioMérieux SA:

bioMérieux SA is headquartered in Marcy l'Etoile, France and was founded in1963. The company is engaged in manufacturing of in-vitro diagnostic solutions driven by the pioneering spirit and unrelenting commitment with an aim to improve public health worldwide. The company operates its business through two business segments which are clinical application and industrial application in which clinical application is the market focused segment. The company has two product categories which are by specialty and by pathology in these by pathology is the market focused category.

For instance,

  • In July 2020, bioMérieux SA launched biofire mycoplasma test used for mycoplasma detection in biopharmaceutical product. This initiative helped the company to expand their product portfolio which allowed it to generate more revenue.

The company has presence across North America, Europe, Middle East and Africa, South America and Asia-Pacific. The company has various subsidiaries involving bioMérieux UK Ltd (U.K.), Biomérieux Brasil S.A. (Brazil), bioMérieux Japan Ltd. (Japan), Biomerieux Austria Gmbh (Austria), Biomerieux Italia Spa (Italy) among others.